Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 282

Results For "ED"

7852 News Found

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development
News | January 27, 2025

SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development

Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats


AstraZeneca plans US$ 570 million investment in Canada
News | January 27, 2025

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies


Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
News | January 25, 2025

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Q3 FY25 revenue up 24% to Rs 3,230 crore


Merck inaugurates expansion of its Peenya facility in Bengaluru
News | January 25, 2025

Merck inaugurates expansion of its Peenya facility in Bengaluru

Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region


Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
News | January 24, 2025

Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr

Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore


Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
News | January 24, 2025

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase


Alivus Life Sciences delivers 12% revenue growth
News | January 24, 2025

Alivus Life Sciences delivers 12% revenue growth

EBITDA margins expand to 31.3%


Neuland Labs board approves Capex of Rs. 342 Cr
News | January 23, 2025

Neuland Labs board approves Capex of Rs. 342 Cr

The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27


Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS
Drug Approval | January 23, 2025

Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS

The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS